@prefix biolink: .
@prefix ns1: .
@prefix this: .
@prefix sub: .
@prefix schema: .
@prefix np: .
@prefix dct: .
@prefix rdf: .
@prefix xsd: .
@prefix rdfs: .
@prefix orcid: .
@prefix prov: .
@prefix npx: .
sub:Head {
this: a np:Nanopublication;
np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo .
}
sub:assertion {
biolink:category biolink:Disease .
sub:association a rdf:Statement;
rdf:object ;
rdf:predicate biolink:treats;
rdf:subject ;
rdfs:label "\"Patients should not be treated with epirubicin hydrochloride injection if they have any of the following conditions: * cardiomyopathy and/or heart failure, recent myocardial infarction or severe arrhythmias [see Warnings and Precautions (5.3 * Previous treatment with maximum cumulative dose of anthracyclines [see Warnings and Precautions (5)] . * Hypersensitivity to epirubicin hydrochloride, other anthracyclines, or anthracenediones [see Adverse Reactions (6.2)]. Patients should not be treated with epirubicin hydrochloride injection if they have any of the following conditions: baseline neutrophil count < 1500 cells/mm 3; (4).\"";
biolink:provided_by ;
biolink:relation schema:MedicalContraindication .
biolink:category biolink:Drug .
}
sub:provenance {
sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}
sub:pubinfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
npx:hasSignature "cfZWQTQiNlk6ICPV2Q7GO9Lf1V0GGDwZIIfflMKG2X0C6xNpWaAcfG0GObHXJEx8GCPjb9++yJNWuCsZ9awpjOWObcBRkcqn7/xrKlSsNj23DQDDstVh9ThhBx2aH6hAlkKQnkMWzcnsRAFxtQQwahdUDBANKr8hdUb2BaxpUBg=";
npx:hasSignatureTarget this: .
this: dct:created "2021-08-25T13:54:02.882+02:00"^^xsd:dateTime;
dct:creator orcid:0000-0002-1468-3557;
ns1:wasCreatedFromProvenanceTemplate ;
ns1:wasCreatedFromPubinfoTemplate ;
ns1:wasCreatedFromTemplate .
}